Lilly Settles Zyprexa State Claims In $62M Deal
The attorneys general alleged that Lilly marketed Zyprexa for uses that the U.S. Food and Drug Administration had not approved. The company also allegedly failed to adequately disclose the drug’s potential side effects to health care providers.
In settling, Lilly agreed to not promote Zyprexa for off-label uses. Lilly also agreed to detail...
To view the full article, register now.